ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

Adcetris Granted Approval For Hodgkin’s Lymphoma and ALCL

September 30, 2011

Society Growth continues, With OS The Largest; ASCO Plans to Reduce flow Of Medical Oncologists; AACR To Impose Page Charges for “Cancer Research:

May 31, 1985

Researchers Plan to Extend Phase IIa Asonep Trial

August 29, 2014

Senate Bill Includes $10 Billion for NIH

February 6, 2009

Cancer Genetics Network approved By NCI Advisors, To Start With 8 Centers

November 29, 1996

Surgical Oncology Planners Develop NCPP research Approaches, Projects

May 24, 1974